How to buy Landos Biopharma Inc stock (Landos Biopharma Inc)

Landos Biopharma Inc is a biotechnology business based in the US. Landos Biopharma Inc shares (LABP) are listed on the NASDAQ and all prices are listed in US Dollars. Landos Biopharma Inc employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Landos Biopharma stock

Buy Landos Biopharma Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Landos Biopharma Inc stock price (NASDAQ: LABP)

Use our graph to track the performance of LABP stocks over time.

Landos Biopharma Inc shares at a glance

• Key figures

Information last updated 2024-07-24.

52-week range	$3.53 - $22.94
50-day moving average more info button	$20.19
200-day moving average more info button	$8.35
Wall St. target price	$12.71
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.00

Is it a good time to buy Landos Biopharma Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Landos Biopharma Inc financials

Gross profit TTM	$18 million
Return on assets TTM	-39.38%
Return on equity TTM	-70.67%
Profit margin	0%
Book value	$7.43
Market Capitalization more info button	$71.7 million

TTM: trailing 12 months

Landos Biopharma Inc share dividends

We're not expecting Landos Biopharma Inc to pay a dividend over the next 12 months.

You may also wish to consider:

Have Landos Biopharma Inc's shares ever split?

Landos Biopharma Inc's shares were split on a 1:10 basis on 25 May 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Landos Biopharma Inc shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Landos Biopharma Inc shares which in turn could have impacted Landos Biopharma Inc's share price.

Landos Biopharma Inc share price volatility

Over the last 12 months, Landos Biopharma Inc's shares have ranged in value from as little as $3.525 up to $22.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Landos Biopharma Inc's is 0.143. This would suggest that Landos Biopharma Inc's shares are less volatile than average (for this exchange).

To put Landos Biopharma Inc's beta into context you can compare it against those of similar companies.

• Leap Therapeutics (LPTX.US): 0.217
• Allakos (ALLK.US): 1.024

Landos Biopharma Inc overview

Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Frequently asked questions

What percentage of Landos Biopharma Inc is owned by insiders or institutions?
Currently 9.888% of Landos Biopharma Inc shares are held by insiders and 52.041% by institutions. How many people work for Landos Biopharma Inc?
Latest data suggests 19 work at Landos Biopharma Inc. When does the fiscal year end for Landos Biopharma Inc?
Landos Biopharma Inc's fiscal year ends in December. Where is Landos Biopharma Inc based?
Landos Biopharma Inc's address is: 1800 Kraft Drive, Blacksburg, VA, United States, 24060 What is Landos Biopharma Inc's ISIN number?
Landos Biopharma Inc's international securities identification number is: US5150691021